By


Oncora Medical teams up with oncologists at N.Y.’s largest health system

See more here

By


Palvella Therapeutics to Present Update on PTX-022 at Pachyonychia Congenita Project Patient Support Meeting in London, UK

See more here

By


Melior Pharmaceuticals Enrolls Last Subject in Phase 2b Study with Tolimidone for Type 2 Diabetes
– Last subject randomized in Phase 2b study-

– Study randomized 433 subjects across 61 sites in 2 countries- 

See more here

By


Relmada Therapeutics to Present Clinical Data on the Effect of REL-1017 on BDNF Plasma Levels
Findings of REL-1017 Effect on BDNF Plasma Levels to be Presented at the Annual Meeting of the American College of Neuropsychopharmacology 

See more here

By


VenatoRx Pharmaceuticals and Everest Medicines ll Limited Announce Exclusive License Agreement for cefepime/VNRX-5133
VenatoRx is eligible to receive up to $114 million, including upfront milestone payments, in addition to royalties 

See more here

By


Mebias Discovery Receives Grant from NIDA to Advance its Signaling-Pathway Selective MU-Opioid Receptor Drug Candidate
Preclinical Studies of lead molecules have shown absence of respiratory depression, rewarding behavior, sedation, and constipation associated with traditional opioids    

See more here

By


Corbus Pharmaceuticals Expands Target Indications by Adding More Than 600 Compounds Focused on the Endocannabinoid System from Jenrin Discovery; Includes CRB-4001 with Planned NIH-Supported Phase 2 Study

See more here

By


ENB Therapeutics Closes Series A Round of Funding
Remiges led the Series A round of Financing  

See more here

By


Relmada Therapeutics Provides Enrollment Update in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder
Trial Enrolling Well, with Approximately 25% of Targeted Subjects Recruited Top-line Data Expected in First Half of 2019  

See more here